X News Alert United States Steel Corp (X) 36.00 11/18/2014 2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
United States Steel Corp (X) 36.00 $X

U.S. Steel Realigns Operating Units to Meet Strategic Goals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 1:40PM CST
U.S. Steel (X) is realigning its three business segments as part of its Carnegie Way program.
NUE: 54.36 (+0.22), MTL: 0.83 (+0.02), X: 36.00 (-0.11)

United States Steel Names Leadership For Service Center, Industrial And Mining Solutions
PR Newswire - Tue Nov 18, 8:51AM CST
United States Steel Corporation (NYSE: X) today announced the executive leadership for three of the company's newly created commercial entities. Joseph R. Scherrbaum will serve as acting vice president - Industrial Solutions, Geoff M. Turk will serve as vice president - Service Center Solutions and Lawrence W. Sutherland will serve as acting head - Mining Solutions, effective Jan. 1, 2015.
X: 36.00 (-0.11)

Post Earnings Update: U.S. Steel Has Sunk 5.0% Lower in Past 2 Weeks (X)
Comtex SmarTrend(R) - Mon Nov 17, 4:21PM CST
When U.S. Steel (NYSE:X) reported earnings two weeks ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.20 on sales of $4.5 billion. U.S. Steel actually reported earnings of $2.16 per share on sales of $4.6 billion, beating EPS estimates by $0.96 and beating revenue estimates by $50.6 million. Since the company's report, shares of U.S. Steel have fallen from $38.15 to $36.24, representing a loss of 5.0% in the past 20 days.
X: 36.00 (-0.11)

Should U.S. Steel (X) Stock Be in Your Portfolio Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 10:40AM CST
U.S. Steel (X) has been upgraded to a Zacks Rank #1 (Strong Buy) by Zacks Investment Research.
STLD: 22.82 (+0.18), CRS: 51.02 (+0.30), NUE: 54.36 (+0.22), X: 36.00 (-0.11)

Companhia Siderurgica Posts Q3 Loss on Weak Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:30AM CST
Companhia Siderurgica Nacional (SID) or CSN's third-quarter 2014 results slipped into losses, amounting to R$250.4 million (US$110.3 million). Loss per share was R$0.18 or approximately 8 cents per American Depository Receipt (ADR).
SID: 2.50 (-0.10), NUE: 54.36 (+0.22), MTL: 0.83 (+0.02), X: 36.00 (-0.11)

United States Steel Corporation Establishes New Management Structure
PR Newswire - Mon Nov 17, 8:30AM CST
United States Steel Corporation (NYSE: X) has announced another logical next step in the company's Carnegie Way transformation journey. By Jan. 1, 2015, the company's reporting segments - North American Flat-Rolled, Tubular and U. S. Steel Europe - will be realigned to achieve three strategic goals:
X: 36.00 (-0.11)

Silvercorp Metals Inc. (SVM) in Focus: Stock Surges 18.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:21AM CST
Silvercorp Metals Inc. (SVM) was a big mover last session, as the company saw its shares rise above 18% on the day.
MTEX: 21.67 (-0.84), MERC: 13.68 (-0.04), X: 36.00 (-0.11), SVM: 1.59 (+0.12)

Steel Stocks under Review - AK Steel Holding, United States Steel, Gerdau, Steel Dynamics, and Reliance Steel and Aluminum
PR Newswire - Mon Nov 17, 8:20AM CST
Investor-Edge has initiated coverage on the following equities: AK Steel Holding Corporation (NYSE: AKS), United States Steel Corporation (NYSE: X), Gerdau S.A. (NYSE: GGB), Steel Dynamics Inc. (NASDAQ: STLD), and Reliance Steel and Aluminum Company (NYSE: RS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 14, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,634.74, down 0.10% and the NASDAQ Composite closed at 4,688.54, up 0.18%. The S&P 500 finished the session 0.02% higher at 2,039.82. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Materials Sector Index ended the day at 309.43, up 0.32%, with the index advancing 5.37% in the last one month. Register for your complimentary reports on these five stocks at:
STLD: 22.82 (+0.18), RS: 64.51 (-0.07), GGB: 4.03 (-0.07), AKS: 6.39 (-0.05), X: 36.00 (-0.11)

InsiderInsights.com Daily Round Up 11/12/14: DVA, PSEC, MRC, SUMR
InsiderInsights - at Seeking Alpha - Fri Nov 14, 3:44PM CST

HAS: 56.12 (-0.25), CJES: 17.98 (-0.53), FB: 74.34 (+0.10), MRC: 21.80 (+0.10), SUMR: 2.83 (+0.04), MYL: 56.24 (+1.11), GOOG: 535.03 (-1.48), GSAT: 2.55 (-0.25), CHRS: 13.16 (+0.01), GGP: 25.91 (+0.06), DVA: 75.23 (-0.28), Q: 57.33 (+0.90), SPW: 92.78 (+0.30), RCPT: 102.98 (-1.24), DATA: 82.10 (-1.21), X: 36.00 (-0.11), PSEC: 9.68 (+0.02), SCHW: 28.76 (+0.21), ERII: 4.90 (+0.20)

U. S. Steel Tubular Products Honors Jeffrey L. Ventura With Chief Roughneck Award
PR Newswire - Thu Nov 13, 12:11PM CST
U. S. Steel Tubular Products, Inc., a subsidiary of United States Steel Corporation (NYSE: X), announced that Jeffrey L. Ventura, president and chief executive officer of Range Resources, is the recipient of the Chief Roughneck Award for 2014. The announcement was made today at the 85th annual meeting of the Independent Petroleum Association of America.
X: 36.00 (-0.11)

5 Stocks With Big Insider Buying: Seattle Genetics and More
at The Street - Thu Nov 13, 12:05PM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
CJES: 17.98 (-0.53), WWWW: 16.77 (+0.21), SGEN: 37.80 (+1.95), CHK: 23.06 (-0.32), X: 36.00 (-0.11)

AK Steel (AKS) Reaches New Labor Agreement with USW - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 6:09PM CST
AK Steel (AKS) has announced the ratification of a new three-year labor agreement by the members of USW Local 1915.
STLD: 22.82 (+0.18), NUE: 54.36 (+0.22), AKS: 6.39 (-0.05), X: 36.00 (-0.11)

Mechel Posts Operational Data, Fails to Meet Listing Norms - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:48PM CST
Mechel (MTL) releases its third-quarter operational results and receives notice from NYSE regarding defiance of ADR norms.
NUE: 54.36 (+0.22), MTL: 0.83 (+0.02), X: 36.00 (-0.11)

Nucor (NUE) Suspends Production at Louisiana Plant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:50PM CST
Nucor Corporation (NUE) announced that an equipment failure has occurred at Nucor Steel Louisiana in St. James Parish. It is associated with a major failure experienced by the process gas heater on Nov 2.
NUE: 54.36 (+0.22), MTL: 0.83 (+0.02), X: 36.00 (-0.11)

Look for Shares of U.S. Steel to Potentially Rebound after Yesterday's 4.47% Sell Off
Comtex SmarTrend(R) - Tue Nov 11, 3:51PM CST
U.S. Steel (NYSE:X) traded in a range yesterday that spanned from a low of $35.02 to a high of $36.45. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $35.11 on volume of 7.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
X: 36.00 (-0.11)

SmarTrend Watching for Potential Rebound in Shares of U.S. Steel After 4.47% Loss
Comtex SmarTrend(R) - Tue Nov 11, 3:50PM CST
U.S. Steel (NYSE:X) traded in a range yesterday that spanned from a low of $35.02 to a high of $36.45. Yesterday, the shares fell 4.5%, which took the trading range below the 3-day low of $35.11 on volume of 7.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
X: 36.00 (-0.11)

U.S. Steel (X) Approaches New Downside Target of $35.69
Comtex SmarTrend(R) - Tue Nov 11, 9:01AM CST
Shares of U.S. Steel (NYSE:X) have bearishly opened below the pivot of $37.12 today and have reached the first support level of $36.19. Analysts will be watching for a cross of the next downside pivot targets of $35.69 and $34.26.
X: 36.00 (-0.11)

AK Steel (AKS) Up on Winning NOES Trade Cases - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 2:04PM CST
AK Steel's (AKS) shares climbed after the ITC reached a positive decision that imposed antidumping orders on six nations.
STLD: 22.82 (+0.18), NUE: 54.36 (+0.22), AKS: 6.39 (-0.05), X: 36.00 (-0.11)

LB Foster Downgraded to Strong Sell on Weak Q3 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 1:50PM CST
On Nov 8, 2014, Zacks Investment Research downgraded LB Foster Co. (FSTR) to a Zacks Rank #5 (Strong Sell) from a Zacks Rank #3 (Hold) primarily driven by woeful quarterly results.
FSTR: 50.93 (-0.05), MTL: 0.83 (+0.02), X: 36.00 (-0.11)

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago U.S. Steel Is Down 1.5% (X)
Comtex SmarTrend(R) - Mon Nov 10, 1:43PM CST
A week ago on October 28th, 2014 U.S. Steel (NYSE:X) reported earnings and analysts, on average, expected earnings of $1.20 on sales of $4.5 billion. U.S. Steel actually reported earnings of $2.16 per share on sales of $4.6 billion, beating EPS estimates by $0.96 and beating revenue estimates by $50.6 million. Since the company's report, shares of U.S. Steel have fallen from $38.15 to $37.57, representing a loss of 1.5% in the past 13 days.
X: 36.00 (-0.11)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading